Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease | Zendy

Eugene Braunwald | Zendy; Michaël Domanski | Zendy; Sarah Fowler | Zendy; Nancy L. Geller | Zendy; Bernard J. Gersh | Zendy; Judith Hsia | Zendy; Marc A. Pfeffer | Zendy; Madeline Murguia Rice | Zendy; Yves Rosenberg | Zendy; Jean L. Rouleau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease

Author(s) -

Eugene Braunwald,

Michaël Domanski,

Sarah Fowler,

Nancy L. Geller,

Bernard J. Gersh,

Judith Hsia,

Marc A. Pfeffer,

Madeline Murguia Rice,

Yves Rosenberg,

Jean L. Rouleau

Publication year - 2004

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa042739

Subject(s) - medicine , trandolapril , cardiology , ejection fraction , hazard ratio , heart failure , myocardial infarction , coronary artery disease , angiotensin converting enzyme , placebo , ace inhibitor , blood pressure , confidence interval , alternative medicine , pathology

Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research